Gadofosveset Injectable Solution 0.25 mmol/mL Suppliers & Bulk Manufacturers

Available Forms: Injectable Solution

Available Strengths: 0.25 mmol/mL

Reference Brands: Ablavar (US), Vasovist (EU)

Category: Contrast Agent

Gadofosveset trisodium 0.25 mmol/mL, an albumin-binding blood-pool MRI agent for angiography that has been withdrawn from major markets. For radiology buyers checking remaining registrations and alternatives.

Product Description:

Gadofosveset trisodium was a blood-pool MRI contrast agent. A diphenylcyclohexyl phosphate group binds it reversibly to serum albumin, which keeps it in the circulation far longer than extracellular agents and raises its relaxivity, so vessels could be imaged at high resolution with a small gadolinium dose. It was supplied as a 0.25 mmol/mL solution for intravenous injection. The recommended dose is 0.03 mmol per kg of body weight.

Its approved use was MR angiography to assess aorto-iliac occlusive disease in adults with known or suspected peripheral vascular disease. Imaging could combine a first-pass arterial phase with a later steady-state phase while the agent stayed in the blood. The product has been withdrawn from major markets, including the European Union and the United States, and most departments now perform MR angiography with standard extracellular agents or non-contrast techniques. As with every gadolinium agent, renal screening and caution in severe kidney disease applied.

Sourcing notes. Supply depends on any registrations that still exist, and for most buyers there is no current source. Treat any offer with caution: insist on proof of registration in the country of sale, a batch CoA, GMP certificate and CoPP, and an expiry date well ahead of planned use, since remaining stock may be old. Do not accept relabelled or repacked units. Hospitals that need vascular imaging should ask their radiologists to name a currently registered agent and write the tender around the procedure, so suppliers can respond with products they can deliver.